| アブストラクト | 3,4-Methylenedioxymethamphetamine (MDMA) is currently being investigated as an adjunctive treatment to therapy for posttraumatic stress and other anxiety related disorders in clinical trials. Within the next few years MDMA-assisted therapy is projected for approval by regulatory authorities. MDMA's primary mechanism of action includes modulation of monoamine signaling by increasing release and inhibiting reuptake of serotonin, norepinephrine, and, to a lesser extent, dopamine. This pharmacology affects sympathomimetic physiology. In controlled trials, special attention has been given to cardiovascular adverse events (AEs), because transient increases in heart rate and blood pressure have been observed during the MDMA-assisted therapy sessions. Finding and quantifying the potential drivers of cardiac AEs in clinical trials is difficult since only a relatively small number of participants have been included in these studies, and a limited set of allowed concomitant drugs has been studied. In this study a more diverse set of reports from the FDA Adverse Event Reporting System was surveyed. We found 17 cases of cardiovascular AEs, in which the individuals had taken one or more substances in addition to MDMA. Interestingly, all of those concomitant medications and illicit substances, including opioids, stimulants, anticholinergics, and amphetamines, had been previously associated with cardiovascular AEs. Furthermore, in none of the reports MDMA was marked as the primary suspect. |
|---|
| ジャーナル名 | Frontiers in psychiatry |
|---|
| Pubmed追加日 | 2023/6/5 |
|---|
| 投稿者 | Makunts, Tigran; Dahill, Diane; Jerome, Lisa; de Boer, Alberdina; Abagyan, Ruben |
|---|
| 組織名 | MAPS Public Benefit Corporation, San Jose, CA, United States.;Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California,;San Diego, San Diego, CA, United States.;Tulip Medical Consulting LLC, Port Townsend, WA, United States. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37275981/ |
|---|
